KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Operating Expenses (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Operating Expenses data on record, last reported at $183.7 million in Q4 2025.

  • For Q4 2025, Operating Expenses changed 0.16% year-over-year to $183.7 million; the TTM value through Dec 2025 reached $717.2 million, up 7.13%, while the annual FY2025 figure was $717.2 million, 7.13% up from the prior year.
  • Operating Expenses reached $183.7 million in Q4 2025 per AMRX's latest filing, down from $201.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $201.3 million in Q3 2025 and bottomed at $139.0 million in Q2 2021.
  • Average Operating Expenses over 5 years is $157.7 million, with a median of $153.0 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: rose 19.65% in 2021, then dropped 7.82% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $156.4 million in 2021, then fell by 7.82% to $144.2 million in 2022, then rose by 7.65% to $155.2 million in 2023, then increased by 18.2% to $183.4 million in 2024, then rose by 0.16% to $183.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $183.7 million in Q4 2025, $201.3 million in Q3 2025, and $173.3 million in Q2 2025.